Characterization of azurocidin as a permeability factor in the Retina: Involvement in VEGF-induced and early diabetic blood-retinal barrier breakdown

Investigative Ophthalmology and Visual Science

Volumn 49, Issue 2, 2008, Pages 726-731

  Skondra, Dimitra ^a   Noda, Kousuke ^a   Almulki, Lama ^a   Tayyari, Faryan ^a   Frimmel, Sonja ^a   Nakazawa, Toru ^a   Kim, Ivana K ^a   Zandi, Souska ^a   Thomas, Kennard L ^a   Miller, Joan W ^a   Gragoudas, Evangelos S ^a   Hafezi Moghadam, Ali ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APROTININ; AZUROCIDIN; EVANS BLUE; VASCULOTROPIN; ANTIMICROBIAL CATIONIC PEPTIDE; CARRIER PROTEIN; CATIONIC ANTIMICROBIAL PROTEIN CAP 37, HUMAN; MONOCYTE CHEMOTACTIC PROTEIN; PLASMA PROTEIN; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD RETINA BARRIER; BLOOD VESSEL PERMEABILITY; BROWN NORWAY RAT; CELL INTERACTION; CONTROLLED STUDY; DIABETIC RETINOPATHY; DOSE RESPONSE; LEUKOCYTE; MALE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; RAT; STREPTOZOCIN DIABETES; ANIMAL; CAPILLARY PERMEABILITY; DRUG ANTAGONISM; DRUG EFFECT; EXPERIMENTAL DIABETES MELLITUS; LONG EVANS RAT; METABOLISM; RETINA BLOOD VESSEL;

ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; APROTININ; BLOOD PROTEINS; BLOOD-RETINAL BARRIER; CAPILLARY PERMEABILITY; CARRIER PROTEINS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC RETINOPATHY; EVANS BLUE; MALE; MONOCYTE CHEMOATTRACTANT PROTEINS; RATS; RATS, INBRED BN; RATS, LONG-EVANS; RETINAL VESSELS; SERINE PROTEINASE INHIBITORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 40649099152     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.07-0405     Document Type: Article

References (34)

1. Kurose I, Anderson DC, Miyasaka M, et al. Molecular determinants of reperfusion-induced leukocyte adhesion and vascular protein leakage. Circ Res. 1994;74:336-343.
2. Del Maschio A, Zanetti A, Corada M, et al. Polymorphonuclear leukocyte adhesion triggers the disorganization of endothelial cell-to-cell adherens junctions. J Cell Biol. 1996;135:497-510.
3. Bolton SJ, Anthony DC, Perry VH. Loss of the tight junction proteins occludin and zonula occludens-1 from cerebral vascular endothelium during neutrophil-induced blood-brain barrier breakdown in vivo. Neuroscience. 1998;86:1245-1257.
4. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 1992;359:843-845.
5. Ikeda E, Achen MG, Breier G, Risau W. Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells. J Biol Chem. 1995;270: 19761-19766.
6. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 1983;219:983-985.
7. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyper-permeability, and angiogenesis. Am J Pathol. 1995;146:1029-1039.
8. Ishida S, Usui T, Yamashiro K, et al. VEGF164 is proinflammatory in the diabetic retina. Invest Ophthalmol Vis Sci. 2003;44:2155-2162.
9. Qaum T, Xu Q, Joussen AM, et al. VEGF-initiated blood-retinal barrier breakdown in early diabetes. Invest Ophthalmol Vis Sci. 2001;42:2408-2413.
10. Miyamoto K, Khosrof S, Bursell SE, et al. Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc Natl Acad Sci USA. 1999;96:10836-10841.
11. Barouch FC, Miyamoto K, Allport JR, et al. Integrin-mediated neutrophil adhesion and retinal leukostasis in diabetes. Invest Ophthalmol Vis Sci. 2000;41:1153-1158.
12. Joussen AM, Poulaki V, Qin W, et al. Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo. Am J Pathol. 2002;160:501-509.
13. Miyamoto K, Khosrof S, Bursell SE, et al. Vascular endothelial growth factor (VEGF)-induced retinal vascular permeability is mediated by intercellular adhesion molecule-1 (ICAM-1). Am J Pathol. 2000;156:1733-1739.
14. Pereira HA, Spitznagel JK, Pohl J, et al. CAP 37, a 37 kD human neutrophil granule cationic protein shares homology with inflammatory proteinases. Life Sci. 1990;46:189-196.
15. Campanelli D, Detmers PA, Nathan CF, Gabay JE. Azurocidin and a homologous serine protease from neutrophils: differential antimicrobial and proteolytic properties. J Clin Invest. 1990;85:904-915.
16. Watorek W. Azurocidin - inactive serine proteinase homolog acting as a multifunctional inflammatory mediator. Acta Biochim Pol. 2003;50:743-752.
17. Gautam N, Olofsson AM, Herwald H, et al. Heparin-binding protein (hoursBP/CAP37): a missing link in neutrophil-evoked alteration of vascular permeability. Nat Med. 2001;7:1123-1127.
18. Reese TS, Karnovsky MJ. Fine structural localization of a blood-brain barrier to exogenous peroxidase. J Cell Biol. 1967;34:207-217.
19. Janzer RC, Raff MC. Astrocytes induce blood-brain barrier properties in endothelial cells. Nature. 1987;325:253-257.
20. Nakazawa T, Matsubara A, Noda K, et al. Characterization of cytokine responses to retinal detachment in rats. Mol Vis. 2006;12:867-878.
21. Nakazawa T, Tomita H, Yamaguchi K, et al. Neuroprotective effect of nipradilol on axotomized rat retinal ganglion cells. Curr Eye Res. 2002;24:114-122.
22. Xu Q, Qaum T, Adamis AP. Sensitive blood-retinal barrier breakdown quantitation using Evans blue. Invest Ophthalmol Vis Sci. 2001;42:789-794.
23. Emanueli C, Salis MB, Van Linthout S, et al. Akt/protein kinase B and endothelial nitric oxide synthase mediate muscular neovascularization induced by tissue kallikrein gene transfer. Circulation. 2004;110:1638-1644.
24. Engles L. Review and application of serine protease inhibition in coronary artery bypass graft surgery. Am J Health Syst Pharm. 2005;62:S9-S14.
25. Petersen LC, Birktoft JJ, Flodgaard H. Binding of bovine pancreatic trypsin inhibitor to heparin binding protein/CAP37/azurocidin: interaction between a Kunitz-type inhibitor and a proteolytically inactive serine proteinase homologue. Eur J Biochem. 1993;214:271-279.
26. Gao G, Shao C, Zhang SX, Dudley A, Fant J, Ma JX. Kallikrein-binding protein inhibits retinal neovascularization and decreases vascular leakage. Diabetologia. 2003;46:689-698.
27. Peters DC, Noble S. Aprotinin: an update of its pharmacology and therapeutic use in open heart surgery and coronary artery bypass surgery. Drugs. 1999;57:233-260.
28. Karkouti K, Beattie WS, Dattilo KM, et al. A propensity score case-control comparison of aprotinin and tranexamic acid in high-transfusion- risk cardiac surgery. Transfusion. 2006;46:327-338.
29. Mangano DT, Tudor IC, Dietzel C. The risk associated with aprotinin in cardiac surgery. N Engl J Med. 2006;354:353-365.
30. Lu M, Perez VL, Ma N, et al. VEGF increases retinal vascular ICAM-1 expression in vivo. Invest Ophthalmol Vis Sci. 1999;40:1808-1812.
31. Joussen AM, Poulaki V, Mitsiades N, et al. Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. FASEB J. 2002;16:438-440.
32. Manduteanu I, Voinea M, Serban G, Simionescu M. High glucose induces enhanced monocyte adhesion to valvular endothelial cells via a mechanism involving ICAM-1, VCAM-1 and CD18. Endothe- lium. 1999;6:315-324.
33. Moore TC, Moore JE, Kaji Y, et al. The role of advanced glycation end products in retinal microvascular leukostasis. Invest Ophthalmol Vis Sci. 2003;44:4457-4464.
34. Lu M, Kuroki M, Amano S, et al. Advanced glycation end products increase retinal vascular endothelial growth factor expression. J Clin Invest. 1998;101:1219-1224.